ClinicalTrials.gg
CompletedNCT07462949EC50 via TCIUpdated Sep 16, 2026

EC50 of Ciprofol Combined With Remifentanil for Inhibiting Tracheal Responses in Patients Undergoing Gynecological Surgery: a Two-phase Up-and-down Sequential Allocation Study

An interventional study of Cipofol combined with remifentanil administered via target-controlled infusion in Elective Surgery, Target Controlled Infusion (TCI) and Noxious Stimuli, sponsored by Guangzhou General Hospital of Guangzhou Military Command. Completed at 1 site in China. Open to participants aged 19 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Guangzhou General Hospital of Guangzhou Military Command · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

  1. The combined induction of intubation with propofol and remifentanil is widely used in clinical anesthesia, primarily through a single intravenous injection. Target-controlled infusion (TCI) technology, which combines pharmacology with clinical practice, offers a more stable and precise infusion mode;
  2. This project aims to explore the half-effective concentration (EC50) of propofol combined with remifentanil for inhibiting tracheal intubation stimulation through a sequential approach under the monitoring of qNOX pain index.
Read the detailed description

Patients undergoing elective surgery, aged 19 to 55 years, with ASA I or II, were selected for a sequential trial in two stages:

  1. In the first stage, induction dose of ciprofol was fixed at 0.4 mg/kg, and the EC50 and EC95 (exploratory) of remifentanil were measured.
  2. In the second stage, the concentration of remifentanil was fixed, and the EC50 and EC95 (exploratory) of ciprofol were measured. The EC and 95% confidence interval (CI) were calculated using the probit probability unit method.
  3. Additionally, the effectiveness of the qNOX index in guiding tracheal intubation stimulation was evaluated by analyzing the receiver operating characteristic (ROC) curves.
02

Conditions studied

  • Elective Surgery
  • Target Controlled Infusion (TCI)
  • Noxious Stimuli
  • Tracheal Intubation Stimulation

Keywords

  • ciprofol
  • remifentanil
  • effective concentration
  • tracheal intubation stimulation
  • qNOX index
03

In context

Lead sponsor

Guangzhou General Hospital of Guangzhou Military Command is the lead sponsor of 46 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective surgery and require general anesthesia with single-lumen endotracheal intubation: I-II, aged between 18 and 55 years, with a (BMI) between 18.5 and 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • 1.Emergency surgery patients, children, pregnant women; 2.Patients with unstable vital signs: such as blood pressure, heart rate, and blood oxygen saturation exceeding the safe range; 3.Patients with craniocerebral trauma or central nervous system lesions; 4.Patients who are allergic to the studied anesthetic drugs, or have recently received other experimental drugs, major surgery, radiotherapy, or chemotherapy; 5.Patients who refuse to sign the form.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
66 participants (actual)

Study arms

  • Other
    Stage 1

    In the first stage, Induction dose of ciprofol was fixed at 0.4 mg/kg, and the EC50 and EC95 of remifentanil were measured. The EC and 95% confidence interval (CI) were calculated using the probit probability unit method.

    Drug: Cipofol combined with remifentanil administered via target-controlled infusion

  • Other
    Stage 2

    In the second stage, the concentration of remifentanil was fixed, and the EC50 and EC95 of ciprofol were measured. The EC and 95% confidence interval (CI) were calculated using the probit probability unit method.

    Drug: Cipofol combined with remifentanil administered via target-controlled infusion

Interventions

  • DrugCipofol combined with remifentanil administered via target-controlled infusion

    Cipofol combined with remifentanil administered via target-controlled infusion for inhibiting tracheal intubation stimulation in adults under qNOX pain index monitoring.

06

What researchers measure

Primary outcomes

  1. Half-effective concentration

    Time frame: Calculated using SPSS software based on the TCI target concentration set during anesthesia induction (the fixed value of the inducing dose does not change over time).

  2. Heart rate

    Time frame: 1 min before intubation, during intubation (within 1~1.5 min) and 5 min after intubation (take the average of three measurements at each stage).

  3. blood pressure

    Time frame: 1 min before intubation, during intubation (within 1~1.5 min) and 5 min after intubation (take the average of three measurements at each stage).

  4. CCS score (intubation score)

    Time frame: within 1 min while intubation (satisfactory intubation conditions simultaneously meet: visible laryngoscope exposure, no vocal cord movement, no coughing, relaxed jaw, no limb movement; otherwise, it is considered unsatisfactory intubation conditions)

Secondary outcomes

  1. BIS index

    Time frame: 1 min before intubation, during intubation (within 1~1.5 min) and 5 min after intubation (take the average of three measurements at each stage).

  2. qNOX index

    Time frame: 1 min before intubation, during intubation (within 1~1.5 min) and 5 min after intubation (take the average of three measurements at each stage).

  3. EMG index

    Time frame: 1 min before intubation, during intubation (within 1~1.5 min) and 5 min after intubation (take the average of three measurements at each stage).

07

Study locations

1 site
  • The Third Affliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510000, China
08

References and documents

Publications

  • 洪桂平. 环泊酚靶控输注在口腔癌根治术中的应用[D]. 中南大学, 2023.
  • Schuller PJ, Pretorius JPG, Newbery KB. Response of the Conox quantitative electroencephalographic monitor to neuromuscular block in awake volunteers. Br J Anaesth. 2025 Sep;135(3):660-667. doi: 10.1016/j.bja.2025.05.023. Epub 2025 Jul 18. PubMed 40683805 ↗
  • Wu B, Zhu W, Wang Q, Ren C, Wang L, Xie G. Efficacy and safety of ciprofol-remifentanil versus propofol-remifentanil during fiberoptic bronchoscopy: A prospective, randomized, double-blind, non-inferiority trial. Front Pharmacol. 2022 Dec 21;13:1091579. doi: 10.3389/fphar.2022.1091579. eCollection 2022. PubMed 36618929 ↗
  • Hu C, Ou X, Teng Y, Shu S, Wang Y, Zhu X, Kang Y, Miao J. Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 Trial. Adv Ther. 2021 Nov;38(11):5484-5500. doi: 10.1007/s12325-021-01914-4. Epub 2021 Sep 24. PubMed 34559359 ↗
  • Teng Y, Ou MC, Wang X, Zhang WS, Liu X, Liang Y, Zuo YX, Zhu T, Liu B, Liu J. Pharmacokinetic and pharmacodynamic properties of ciprofol emulsion in Chinese subjects: a single center, open-label, single-arm dose-escalation phase 1 study. Am J Transl Res. 2021 Dec 15;13(12):13791-13802. eCollection 2021. PubMed 35035718 ↗
  • Lan H, Liu S, Liao Y, Xu B, Lin Y, Wu X, Chen Q, Chen H, Guan X. EC50 and EC95 of Remifentanil for Inhibiting Bronchoscopy Responses in Elderly Patients During Fiberoptic Bronchoscopy Under Ciprofol Sedation: An Up-and-Down Sequential Allocation Trial. Drug Des Devel Ther. 2024 Dec 31;18:6487-6497. doi: 10.2147/DDDT.S490907. eCollection 2024. PubMed 39758227 ↗
  • Vide S, Kreuzer M, Ferreira A, Couto M, Agusti M, Jaramillo S, Schneider G, Garcia PS, Abelha F, Amorim P, Troconiz I, Larson M, Gambus P. Cortical, subcortical, brainstem and autonomic responses to nociception under total intravenous anesthesia. J Clin Anesth. 2025 Apr;103:111825. doi: 10.1016/j.jclinane.2025.111825. Epub 2025 Apr 12. PubMed 40220354 ↗
  • Kox WJ, von Heymann C, Heinze J, Prichep LS, John ER, Rundshagen I. Electroencephalographic mapping during routine clinical practice: cortical arousal during tracheal intubation? Anesth Analg. 2006 Mar;102(3):825-31. doi: 10.1213/01.ane.0000197776.26307.fa. PubMed 16492836 ↗
  • Ledowski T. Objective monitoring of nociception: a review of current commercial solutions. Br J Anaesth. 2019 Aug;123(2):e312-e321. doi: 10.1016/j.bja.2019.03.024. Epub 2019 Apr 30. PubMed 31047645 ↗

Individual participant data

Plan to share: No — for privacy protection

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Apr 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 10, 2026
StartActual
Mar 3, 2026
Primary completionActual
Apr 3, 2026
CompletionActual
Apr 6, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462949
Lead sponsor
Guangzhou General Hospital of Guangzhou Military Command
Responsible party
bo xu (Medical Doctor, Guangzhou General Hospital of Guangzhou Military Command) — Principal investigator
First posted
Mar 10, 2026
Start date
Mar 3, 2026
Primary completion
Apr 3, 2026
Completion
Apr 6, 2026
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion